MetaVia Inc.
$1.51
▲
0.8%
2026-04-21 08:17:02
www.metaviatx.com
NCM: MTVA
Explore MetaVia Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.13 M
Current Price
$1.51
52W High / Low
$19.03 / $1.17
Stock P/E
—
Book Value
$2.31
Dividend Yield
—
ROCE
-250.37%
ROE
-1.96%
Face Value
—
EPS
$-7.35
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
8
Beta
0.34
Debt / Equity
3.94
Current Ratio
1.93
Quick Ratio
1.93
Forward P/E
—
Price / Sales
—
Enterprise Value
$-2.92 M
EV / EBITDA
0.21
EV / Revenue
—
Rating
Strong Buy
Target Price
$19.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cadrenal Therapeutics, Inc. | $5.25 | — | $13.09 M | — | -491.51% | -2.6% | $17.5 / $4.21 | $1.17 |
| 2. | aTyr Pharma, Inc. | $0.85 | — | $83.68 M | — | -99.71% | -1.08% | $7.29 / $0.64 | $0.69 |
| 3. | Theravance Biopharma, Inc. | $16.72 | 8.29 | $877.44 M | — | -0.81% | 44.84% | $21.03 / $8.33 | $5.81 |
| 4. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 5. | Galmed Pharmaceuticals Ltd. | $0.75 | — | $4.81 M | — | -38.45% | -64.21% | $2.68 / $0.41 | $3.49 |
| 6. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 7. | Silo Pharma, Inc. | $0.67 | — | $8.38 M | — | -61.55% | -74.57% | $1.19 / $0.22 | $0.47 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.05 M | -3.48 M | -4.3 M | -3.89 M | -5.58 M | — |
| Net Profit | -1.93 M | -3.38 M | -4 M | -3.67 M | -5.17 M | — |
| EPS in Rs | -0.38 | -0.66 | -0.78 | -0.72 | -1.02 | -6.05 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -13.71 M | -28.81 M | -15.89 M | -11.42 M |
| Net Profit | -12.97 M | -27.59 M | -12.47 M | -13.97 M |
| EPS in Rs | -2.55 | -5.42 | -2.45 | -2.74 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 11.12 M | 16.26 M | 22.78 M | 33.53 M |
| Total Liabilities | 5.79 M | 8.33 M | 6.1 M | 11.78 M |
| Equity | 5.33 M | 7.93 M | 16.68 M | 21.75 M |
| Current Assets | 10.88 M | 16.07 M | 22.51 M | 33.53 M |
| Current Liabilities | 5.65 M | 8.27 M | 5.96 M | 11.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -15.7 M | -24.71 M | -10.8 M | -11.71 M |
| Investing CF | -0 M | -0.01 M | -0.05 M | 0.01 M |
| Financing CF | 9.96 M | 18.3 M | -0.08 M | 28.68 M |
| Free CF | -15.7 M | -24.72 M | -10.85 M | -11.71 M |
| Capex | -0 M | -0.01 M | -0.05 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -121.27% | 10.72% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-12-05 | 1:0.0909091 |
| 2023-12-21 | 1:0.125 |
| 2022-09-13 | 1:0.0333333 |